Healthcare-Associated Infections in Ukraine and the Activity of 4-Thiazolidinone Derivatives Against Related Pathogens
NCT Number: NCT06508398
Acronym: HAIsUA
Status: COMPLETED
Study Type: OBSERVATIONAL
Conditions: Nosocomial Infection
Interventions: DIAGNOSTIC_TEST: Microbiological Diagnostic Testing
Sponsor: Danylo Halytsky Lviv National Medical University
Sex: ALL
Age: CHILD, ADULT, OLDER_ADULT
Enrollment: 250
Study Design: Observational Model: |Time Perspective: p
Start Date: 2017-09-01
Completion Date: 2024-06-30
Locations: Danylo Halytsky Lviv National Medical University, Lviv, Lviv Region, 79010, Ukraine

Summary:
The goal of this observational study is to evaluate the species spectrum and biological properties of bacterial and fungal pathogens causing healthcare-associated infections (HAIs) and to investigate the antimicrobial activity of new 4-thiazolidinone derivatives. The main questions it aims to answer are:

What are the common pathogens responsible for HAIs in ICU patients? What is the antimicrobial and antifungal efficacy of 4-thiazolidinone derivatives against these pathogens?

Participants will have their clinical samples collected and analyzed for pathogen identification and susceptibility testing. The study will involve:

Collecting clinical data and samples from ICU patients Conducting microbiological and biochemical tests Screening new antimicrobial compounds for efficacy The study does not involve a comparison group as it focuses on observational data and laboratory analysis.

Primary Outcome Measures: Incidence of Healthcare-Associated Infections (HAIs), The primary outcome measure is to determine the incidence rate of healthcare-associated infections in ICU patients. This will be achieved by collecting and analyzing clinical samples for the presence of bacterial and fungal pathogens. The effectiveness of new 4-thiazolidinone derivatives against these pathogens will also be assessed through antimicrobial susceptibility testing., 12 months
Secondary Outcome Measures: Pathogen Distribution in Healthcare-Associated Infections, The secondary outcome measure focuses on identifying and analyzing the distribution of bacterial and fungal pathogens causing healthcare-associated infections (HAIs) in ICU patients. This involves the collection and examination of clinical samples to determine the prevalence and types of pathogens. Additionally, the study will evaluate the antimicrobial resistance profiles of these pathogens to understand the resistance patterns and effectiveness of current treatment options., 12 months
Other Outcome Measures: Clinical Outcomes of ICU Patients with HAIs, This measure evaluates the clinical outcomes of ICU patients diagnosed with healthcare-associated infections, including length of hospital stay, mortality rates, and readmission rates. The study aims to understand the impact of HAIs on patient recovery and hospital resource utilization., 12 months|Efficacy of 4-Thiazolidinone Derivatives, This measure assesses the antimicrobial and antifungal efficacy of new 4-thiazolidinone derivatives against isolated pathogens. The study involves in vitro testing to determine the minimum inhibitory concentrations (MICs) and compare them to existing treatments., 12 months|Antimicrobial Resistance Mechanisms, This measure investigates the genetic mechanisms of antimicrobial resistance in identified pathogens. The study involves sequencing and molecular analysis to identify resistance genes and their expression patterns., 12 months